Drug intelligence / Profile preview

GALNAC4S-6ST siRNA-1

Development stage
Preclinical
Lead developer
Sirnaomics
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral
01

Overview

GALNAC4S-6ST siRNA-1 is a small interfering RNA (siRNA) designed to silence the expression of the *CHST15* gene, which encodes the enzyme N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase (GALNAC4S-6ST). This enzyme is a critical regulator of glycosaminoglycan sulfation, specifically responsible for the biosynthesis of the chondroitin sulfate E (CS-E) motif by adding a sulfate group to the C6 position of GalNAc(4S). In the context of castration-resistant prostate cancer (CRPC), CS-E has been identified as a driver of androgen-independent growth by activating the IL-6/STAT3 signaling pathway. By utilizing the RNA interference (RNAi) pathway to knock down GALNAC4S-6ST, this siRNA reduces CS-E levels, thereby inhibiting downstream oncogenic signaling and potentially limiting tumor progression in advanced prostate cancer. It is primarily utilized in preclinical research to investigate the therapeutic potential of targeting specific sulfation patterns in the tumor microenvironment.

Other names
CHST15 siRNA-1CHST-15 siRNA-1CHST 15 siRNA-1N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase siRNA-1N-acetylgalactosamine4-sulfate 6-O-sulfotransferase siRNA-1N-acetylgalactosamine-4-sulfate 6-O-sulfotransferase siRNA-1
02

Targets

CHST15 (Carbohydrate sulfotransferase 15)

Beyond the preview

Go deeper on GALNAC4S-6ST siRNA-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GALNAC4S-6ST siRNA-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call